|Table of Contents|

Analysis of the efficacy of stereotactic radiotherapy combined with bevacizumab and PD-1 immunotherapy on brain metastases of non-small cell lung cancer

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2024 16
Page:
3011-3018
Research Field:
Publishing date:

Info

Title:
Analysis of the efficacy of stereotactic radiotherapy combined with bevacizumab and PD-1 immunotherapy on brain metastases of non-small cell lung cancer
Author(s):
ZHANG Yujie1; 2; 3; SHI Hanfei2; 3; MAO Yong4; PAN Dejian1; 2; 3
1.Department of Oncology,the 904th Hospital of Joint Logistic Support Force of PLA,Jiangsu Wuxi 214000,China;2.Wuxi Clinical College of Anhui Medical University,Jiangsu Wuxi 214000,China;3.The Fifth Medical Clinical College of Anhui Medical University,Jiangsu Wuxi 214000,China;4.Department of Oncology,Affiliated Hospital of Jiangnan University,Jiangsu Wuxi 214000,China.
Keywords:
non-small cell lung cancer; brain metastasis; immune checkpoint inhibitors; combination therapy; anti-angiogenic therapy; de-chemotherapy
PACS:
R734.2
DOI:
10.3969/j.issn.1672-4992.2024.16.013
Abstract:
Objective:To investigate the efficacy and adverse reactions of stereotactic radiotherapy(SRT) combined with bevacizumab and programmed cell death-1(PD-1) inhibitor immunotherapy in patients with brain metastases(BM) from advanced non-squamous non-small cell lung cancer(ns-NSCLC).Methods:Clinical data of 119 patients with non-squamous non-small cell lung cancer brain metastasis treated at the 904th Hospital of the Joint Logistics Support Force of PLA and the Affiliated Hospital of Jiangnan University from May 2019 to December 2021 were retrospectively collected and followed up.They were divided into 3 groups according to therapies:Group SP:SRT+chemotherapy,group SBIP:SRT+chemotherapy+bevacizumab+PD-1 inhibitor immunotherapy,group SBI:SRT+bevacizumab+PD-1 inhibitor immunotherapy.The short-term efficacy,survival period,and adverse reactions of each group were compared pairwise.Risk factor analysis was performed on the trial.Results:There was no statistically significant difference in disease control rate (DCR),progress-free survival (PFS),and overall survival (OS) between group SBIP and group SBI,but both were superior to group SP.Group SBI had a significant difference in adverse reaction grading compared to group SBIP,and the incidence of adverse reactions was lower than that of group SBIP.Age,differentiation grade,performance status(PS) score,meningeal metastasis,programmed cell death-ligand 1(PD-L1) expression level and biggest size of lung cancer were independent risk factors for patients in ns-NSCLC BM.In subgroup analyses,the difference in OS between the epidermal growth factor receptor(EGFR) positive and negative groups was not statistically significant.Conclusion:Stereotactic radiotherapy combined with antiangiogenic targeted therapy and immunotherapy can effectively improve the efficacy of patients in ns-NSCLC with brain metastasis,with few adverse reactions and high safety,which is worthy of clinical promotion and application.

References:

［1］ SIEGEL RL,MILLER KD,WAGLE NS,et al.Cancer statistics,2023 ［J］.CA:A Cancer Journal for Clinicians,2023,73(1):17-48.
［2］ LAMBA N,KEARNEY RB,CATALANO PJ,et al.Population-based estimates of survival among elderly patients with brain metastases ［J］.Neuro-oncology,2021,23(4):661-676.
［3］ LAMBA N,WEN PY,AIZER AA.Epidemiology of brain metastases and leptomeningeal disease ［J］.Neuro-oncology,2021,23(9):1447-1456.
［4］ 智欣欣,任胜祥.2023年CSCO指南更新解读：Ⅳ期驱动基因阴性非小细胞肺癌诊疗 ［J］.实用肿瘤杂志,2023,38(05):421-426. ZHI XX,REN SX.Interpretation of updated 2023 CSCO guideline:diagnosis and treatment of stage IV driver-gene negative non-small cell lung cancer［J］.Journal of Practical Oncology,2023,38(05):421-426.
［5］ SOCINSKI MA,NISHIO M,JOTTE RM,et al.IMpower150 final overall survival analyses for Atezolizumab plus Bevacizumab and chemotherapy in first-line metastatic nonsquamous NSCLC ［J］.Journal of Thoracic Oncology,2021,16(11):1909-1924.
［6］ SUGAWARA S,LEE JS,KANG JH,et al.Nivolumab with carboplatin,paclitaxel,and bevacizumab for first-line treatment of advanced nonsquamous non-small-cell lung cancer ［J］.Annals of Oncology,2021,32(9):1137-1147.
［7］ 邱鲁鹏,孙卓雅,赵晓,等.抗血管生成药物联合免疫检查点抑制剂治疗非小细胞肺癌的作用机制及临床应用进展 ［J］.解放军医学院学报,2022,43(12):1288-1292，1297. QIU LP,SUN ZY,ZHAO X,et al.The mechanism and clinical application progress of anti angiogenesis drugs combined with immunocheckpoint inhibitors in the treatment of non-small cell lung cancer ［J］.Academic Journal of Chinese PLA Medical School,2022,43(12):1288-1292，1297.
［8］ LEVIS M,GASTINO A,DE GIORGI G,et al.Modern stereotactic radiotherapy for brain metastases from lung cancer:Current trends and future perspectives based on integrated translational approaches ［J］.Cancers,2023,15(18)：4622.
［9］ 王秋桐,吴爽,刘颖,等.抗血管生成药物靶向治疗进展期非小细胞肺癌的临床研究进展 ［J］.中国新药与临床杂志,2022,41(02):71-78. WANG QT,WU S,LIU Y,et al.Clinical research progress of targeted antiangiogenic drugs in the treatment of advanced non-small cell lung cancer ［J］.Chinese Journal of New Drugs and Clinical Remedies,2022,41(02):71-78.
［10］ WEI X,CHEN Y,JIANG X,et al.Mechanisms of vasculogenic mimicry in hypoxic tumor microenvironments ［J］.Molecular Cancer,2021,20(1):7.
［11］ LU Q,YAN W,ZHU A,et al.Combining spatially fractionated radiation therapy (SFRT) and immunotherapy opens new rays of hope for enhancing therapeutic ratio ［J］.Clinical and Translational Radiation Oncology,2024,44:100691.
［12］ YANG Y,DENG L,YANG Y,et al.Efficacy and safety of combined brain radiotherapy and immunotherapy in non-small-cell lung cancer with brain metastases:A systematic review and Meta-analysis ［J］.Clin Lung Cancer,2022,23(2):95-107.
［13］ QIAN C,LIU C,LIU W,et al.Targeting vascular normalization:a promising strategy to improve immune-vascular crosstalk in cancer immunotherapy ［J］.Frontiers in Immunology,2023,14:1291530.
［14］ CHOI Y,JUNG K.Normalization of the tumor microenvironment by harnessing vascular and immune modulation to achieve enhanced cancer therapy ［J］.Experimental & Molecular Medicine,2023,55(11):2308-2319.
［15］ ZHAO S,REN S,JIANG T,et al.Low-dose Apatinib optimizes tumor microenvironment and potentiates antitumor effect of PD-1/PD-L1 blockade in lung cancer ［J］.Cancer Immunology Research,2019,7(4):630-643.
［16］ HERBST RS,ARKENAU HT,BENDELL J,et al.Phase 1 expansion cohort of ramucirumab plus pembrolizumab in advanced treatment-naive NSCLC ［J］.Journal of Thoracic Oncology,2021,16(2):289-298.
［17］ HELLMANN MD,PAZ-ARES L,BERNABE CARO R,et al.Nivolumab plus Ipilimumab in advanced non-small-cell lung cancer ［J］.The New England Journal of Medicine,2019,381(21):2020-2031.
［18］ LEE SM,SCHULZ C,PRABHASH K,et al.First-line atezolizumab monotherapy versus single-agent chemotherapy in patients with non-small-cell lung cancer ineligible for treatment with a platinum-containing regimen (IPSOS):a phase 3,global,multicentre,open-label,randomised controlled study ［J］.Lancet (London,England),2023,402(10400):451-463.
［19］ SCOCCIANTI S,OLMETTO E,PINZI V,et al.Immunotherapy in association with stereotactic radiotherapy for non-small cell lung cancer brain metastases:results from a multicentric retrospective study on behalf of AIRO ［J］.Neuro-oncology,2021,23(10):1750-1764.
［20］ 潘绵顺,李勇,邱书珺,等.立体定向放射治疗联合贝伐珠单抗治疗脑转移瘤的临床研究 ［J］.立体定向和功能性神经外科杂志,2017,30(05):275-279. PAN MS,LI Y,QIU SJ,et al.Stereotactic radiotherapy with bevacizumab for brain metastases ［J］.Chinese Journal of Stereotactic and Functional Neurosurgery,2017,30(05):275-279.

Memo

Memo:
江苏省无锡市科技发展基金指导性计划项目（编号：202029）
Last Update: 1900-01-01